Myocor
This article was originally published in The Gray Sheet
Executive Summary
Firm raises $18.8 mil. in a private placement of preferred stock, led by St. Paul Venture Capital. The Minneapolis-based company will use the proceeds for Phase I and II U.S. trials of the Myosplint passive implant, intended to improve cardiac performance in late stage heart failure patients by "changing ventricular size and shape and reducing cardiac wall stress," Myocor says